{"id":144296,"date":"2026-02-05T10:15:00","date_gmt":"2026-02-05T15:15:00","guid":{"rendered":"https:\/\/medcitynews.com\/?p=144296"},"modified":"2026-02-05T09:29:49","modified_gmt":"2026-02-05T14:29:49","slug":"debunked-episode-23-companies-vie-for-healthcare-ai-dominance","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/02\/debunked-episode-23-companies-vie-for-healthcare-ai-dominance\/","title":{"rendered":"Debunked Episode 23: Companies Vie for Healthcare AI Dominance"},"content":{"rendered":"\n

There is a sense that the AI in healthcare landscape is shifting as Anthropric and OpenAI<\/a> vie for industry dominance. Both have sought to build up their healthcare offerings over the past year. Debunked Podcast hosts MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, Health Innovation Pitch managing partner, noted that while the companies both offer consumer search tools, underscored by OpenAI for Healthcare’s rollout of Chat GPT Health last month, their differences are more apparent in the tools they offer clinicians and healthcare administrators.<\/p>\n\n\n\n

OpenAI has received backing from hospitals, such as Cedars-Sinai Medical Center, Baylor Scott & White, and Boston Children’s, who are keen to use Open AI in Healthcare in pilots to improve operational efficiency. <\/p>\n\n\n\n

Anthropic has rolled out tools geared to research scientists and clinicians. Its Claude for Healthcare and Claude for Life Sciences users include Banner Health, Sanofi, and Novo Nordisk, among other players.<\/p>\n\n\n\n

There continues to be plenty of opportunities for other companies to apply AI in healthcare and life sciences.<\/p>\n\n\n\n

Samir pointed out that medical information and decision support platform Open Evidence’s<\/a> valuation had soared over the past year. The company, which has signed deals with New England Journal of Medicine, Journal of the American Medical Association, and the National Comprehensive Cancer Network, began 2025 with a $1 billion valuation, climbing to $12 billion in recent weeks.<\/p>\n\n\n\n

Pharma companies also view AI collaborations and partnerships as critical to maintaining a competitive edge in R&D. Arundhati noted Lilly’s collaboration with Nvidia<\/a>, which brings together Nvidia data scientists with Eli Lilly drug discovery at an innovation lab in South San Francisco. GSK announced a partnership with Noetik<\/a> to develop the next generation of cancer therapeutics.<\/p>\n\n\n\n

Arundhati also talked about the unrest in Minneapolis, a place she used to call home. <\/p>\n\n\n\n

Watch the full episode<\/strong>:<\/p>\n\n\n\n